MALVERN, Pa., June 06, 2025 - TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, announced the approval of a new inducement grant for Jim Hagen, the company's Senior Vice President of Strategic Commercial Operations. Effective June 2, 2025, Hagen will receive an option to purchase 75,000 shares of TELA Bio's common stock, along with restricted stock units covering 30,000 shares. The stock options are priced at $1.42 per share, the closing price on the grant date, with a ten-year term. They will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the following 36 months. The restricted stock units will also vest in equal annual installments over four years. These awards are contingent upon Hagen's continued service with TELA Bio.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。